- In September 2024, Merck & Co. Inc. announced that the U.S. Food and Drug Administration (FDA) approved its cancer drug, Keytruda, for the treatment of malignant pleural mesothelioma, a rare cancer associated with asbestos exposure. This approval marked a significant advancement in treatment options for this aggressive form of cancer, providing new hope for patients affected by this life-threatening disease
- In April 2024, Amneal Pharmaceuticals announced the launch of PEMRYDI RTU, the first and only ready-to-use formulation of pemetrexed for injection. Unlike other versions, this product requires no reconstitution, dilution, or refrigeration, offering a more convenient alternative for healthcare providers. The ready-to-use format simplified preparation and administration compared to existing pemetrexed options
- In March 2024, the U.S. Environmental Protection Agency finalized a rule to prohibit ongoing uses of chrysotile asbestos, the only known form of asbestos currently used in or imported to the United States. This move aims to protect public health from the carcinogenic effects of asbestosis
- In February 2024, a significant advancement was reported with the combination of ADI-PEG20 (pegargiminase) and chemotherapy, marking the first such combination in 20 years. This treatment has shown promise in improving survival rates for mesothelioma, a cancer linked to asbestos exposure
- In October 2024, an official from China's National Health Commission announced the opening of 829 sites for the free treatment of patients suffering from pneumoconiosis, a category of occupational lung diseases that includes asbestosis. This initiative aimed to provide accessible healthcare to affected individuals, particularly in regions with high industrial activity
Frequently Asked Questions
The shift toward advanced respiratory therapies and targeted drug delivery, is emerging as a pivotal trend driving the global asbestosis treatment market.
The major factors driving the growth of the asbestosis treatment market are growing need due to Increasing Incidence of Occupational Asbestos Exposure and occupational exposure and rising awareness about early diagnosis and treatment options
The primary challenges include High Treatment Costs and Limited Accessibility and lack of early-stage diagnosis and the slow progression of regulatory changes
The Prednisone segment is expected to dominate the global asbestosis treatment market holding a major market share in 2025, due to its strong anti-inflammatory properties, which help alleviate lung inflammation and improve breathing in asbestosis patients.
Asia-Pacific is the fastest growing region in the global asbestosis treatment market due to the rapid industrialization and increasing awareness about occupational health risks
